文献速递胃肠外科围术期管理与 ERAS

减重手术对胰岛素治疗2型糖尿病患者的影响

The impact of bariatric surgery on insulin-treated type 2 diabetes patients.
PubMed 文献 · Surg Endosc · 2017-08-25

基于安大略减重登记数据,比较RYGB与SG在胰岛素治疗与非胰岛素治疗T2DM患者中的3年结局。两组减重相似,但胰岛素依赖组完全缓解率低,RYGB早期完全缓解率高于SG。

要点

  • 胰岛素治疗T2DM患者减重效果与非胰岛素组相似。
  • 胰岛素依赖组3年完全缓解率仅18.5%,显著低于非胰岛素组66.5%。
  • 胰岛素依赖患者中RYGB早期完全缓解率高于SG。

核心结论

  • RYGB和SG均能有效治疗胰岛素治疗T2DM患者的体重和糖尿病,但胰岛素依赖患者完全缓解率较低,且RYGB在早期年度的完全缓解率更高。

研究设计与样本

  • 回顾性分析安大略减重登记数据,比较RYGB与SG在胰岛素治疗与非胰岛素治疗T2DM患者中的结局,随访3年。

主要发现

  • 共纳入3668例糖尿病患者,其中非胰岛素治疗2872例,胰岛素治疗1187例。
  • 3年时胰岛素组平均减重百分比30.1%,非胰岛素组28.3%(p=0.0673)。
  • 3年时非胰岛素组11.3%使用抗糖尿病药物,胰岛素依赖组59.6%(p<0.0001)。
  • 胰岛素依赖患者中,RYGB组3年胰岛素使用减少26.5%和40%,优于SG组。
  • 非胰岛素治疗患者3年完全缓解率66.5%,胰岛素依赖组18.5%(p<0.0001)。

关键数值与推荐

  • 胰岛素依赖患者完全缓解率:RYGB组第1年8.5% vs SG组5.4%,第2年24.4% vs 21.1%(p<0.0001)。
  • 无论是否使用胰岛素,RYGB组第1年完全缓解率50.7% vs 39.8%,第2年54.6% vs 49.1%(p<0.0001)。

临床怎么用

  • 对于胰岛素治疗的T2DM肥胖患者,RYGB可能提供更高的早期完全缓解率,但需个体化选择术式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Bariatric surgery has been shown to lead to significant improvement in glucose homeostasis, resulting in greater rates of type 2 diabetes mellitus (T2DM) remission. While there is substantial evidence of the benefits of bariatric/metabolic surgery in obese diabetic patients on oral therapy (O-T2D), more evidence is necessary in the case of insulin-treated type 2 diabetes (I-T2D) patients and the selection of surgical procedure. METHODS: Analysis of the Ontario Bariatric Registry data was performed, comparing outcomes of Roux-en-Y-gastric bypass (RYGB) and sleeve gastrectomy (SG) on insulin-treated versus non-insulin-treated T2DM patients. We compared weight loss, medication use and remission rates during a 3-year follow up. RESULTS: A total of 3668 diabetic Bariatric Registry patients underwent surgery from Jan 2010 to Feb 2017, across 7 Bariatric Centers of Excellence in Ontario. Of these 2872 were O-T2D and 1187 were I-T2D. Weight loss was similar between the two groups at 3 years; with mean %WL of 30.1% for the insulin group vs. 28.3% non-insulin (p = 0.0673). At 3 years, 11.3% of the non-insulin and 59.6% of the insulin-dependent group were using anti-diabetic medication (p < 0.0001). Among insulin-dependent patients, RYGB showed greater reduction in insulin use with 26.5 and 40% compared to SG at 3 years. O-T2D patients experienced more complete diabetes remission, with 66.5 vs. 18.5% (p < 0.0001) at 3 years. Complete remission for I-T2D patients was higher in the RYGB group than SG (p < 0.0001) at years 1 and 2 (8.5 vs. 5.4% and 24.4 vs. 21.1%). The same trend was found regardless of insulin use; complete remission higher for RYGB at 1 and 2 years [50.7 vs. 39.8% (p < 0.0001), and 54.6 vs. 49.1% (p < 0.0001)]. CONCLUSION: While both RYGB and SG procedures provide effective treatment for I-T2D patients in terms of weight loss and diabetes, incidence of complete remission for insulin-dependent patients is higher with RYGB in earlier years.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Lemus R, Karni D, Hong D, et al. The impact of bariatric surgery on insulin-treated type 2 diabetes patients. Surg Endosc. 2017. PMID: 28842774. doi:10.1007/s00464-017-5777-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。